INTRODUCTION
Atherosclerosis is a chronic inflammatory disease of the large arteries, characterized by defects in lipid homeostasis. Oxidized lipid antigens within atherosclerotic plaques contribute to disease progression through macrophage differentiation, lipid antigen presentation, and activation of T cell responses. Patients with systemic lupus erythematosus (SLE) have an increased risk of atherosclerosis compared with the general population, with female patients aged 35 to 44 years being over 50 times more likely to experience a cardiovascular event compared with age-matched female controls (1) . Although traditional cardiovascular risk factors (including smoking and hypertension) are common in SLE patients (2), they do not account for the increased cardiovascular risk, which may be due to persistent inflammation and immune cell dysfunction (3) . Dyslipidemia is a conventional risk factor for cardiovascular disease (CVD), but lipids also have potent effects on the immune system. SLE patients have multiple lipid defects including dyslipidemia (3) and altered plasma membrane glycosphingolipid profiles that contribute to abnormal immune cell function (4, 5) .
Invariant natural killer T (iNKT) cells constitute less than 0.1% of peripheral blood mononuclear cells (PBMCs) and are identified by expression of the Va24Ja18 invariant T cell receptor (iTCR) recognizing glycolipid antigen presented via CD1d on antigen-presenting cells (APCs). iNKT cells mediate a balance between immune activation and tolerance through proliferation and rapid release of both proinflammatory and anti-inflammatory cytokines, resulting in immune cell transactivation and modulation (6) . They are implicated in the pathogenesis of many diseases, including autoimmunity, cancer, atherosclerosis, and allergy (7) .
SLE patients have reduced iNKT cell number and defective function, supporting a protective role for iNKT cells in autoimmunity. Functional defects, whereby iNKT cells fail to proliferate upon stimulation with the sponge-derived iNKT cell agonist a-galactosylceramide (a-GalCer), have been attributed to defective CD1d-mediated lipid antigen presentation in SLE patients (8, 9) . Although several observations support a role for iNKT cells in promoting atherogenesis (10) (11) (12) , iNKT cells may play a regulatory role during its early stages by promoting atherosclerosis resolution via increased interleukin-10 (IL-10) production (13) . Consequentially, the role of iNKT cells in human atherogenesis remains unclear.
Understanding the progression of subclinical atherosclerotic plaque is important clinically for long-term CVD outcomes in SLE patients (14) . We investigated the role of iNKT cells in the development of subclinical atherosclerosis in 100 patients with SLE who had no previous history of CVD using vascular ultrasound to quantify the presence of plaque and its composition. In our SLE patient cohort, 36% had subclinical plaque, supporting previous studies (15) . SLE patients with preclinical plaque (SLE-P) had a distinct anti-inflammatory iNKT cell profile characterized by increased activation and IL-4 production, which correlated with serum lipid expression levels and altered lipoprotein composition. Crucially, iNKT cells differentiated in the presence of serum from SLE-P patients induced the polarization of M2-like macrophages in vitro. This protective iNKT cell phenotype was lost in SLE patients who had a cardiovascular event. The results support an atheroprotective role for iNKT cells driven by serum lipids during the early stages of atherosclerosis, which was lost or overwhelmed during the development of clinical atherosclerosis. Furthermore, differences in serum lipid taxonomy were sufficient to cluster patients with and without preclinical plaque and, together with iNKT cell phenotype, could be used to predict atherosclerosis development in SLE patients.
RESULTS
A distinct iNKT cell phenotype in SLE-P patients We examined peripheral blood (PB) iNKT cell frequency and function in SLE patients assessed for preclinical atherosclerosis by carotid and femoral artery ultrasound scan (see Supplementary Materials and Methods). SLE-P patients were older and had longer disease duration and higher mean systolic blood pressure compared with SLE patients without plaque (SLE-NP); however, no association between plaque presence and current or persistent disease activity, medication, or antidouble-stranded DNA antibody or C3 levels was seen (table S1). Healthy donors (HCs; who were not scanned) were selected on the basis of their gender, age, smoking status, and cardiovascular history, which indicated that they were unlikely to have plaque (table S1) .
PB iNKT cell frequency was significantly reduced in SLE-NP patients compared with HCs, confirming previous observations (8, 9) ; however, this reduction was lost in SLE-P patients (see Fig. 1 , A and B, and fig. S1A for gating strategy). This discrepancy was not explained by associations with age, disease duration, systolic blood pressure, treatment (9) , or other clinical features and was stable over time ( fig. S1 , B to E, and table S1). iNKT cells from SLE-P patients also preferentially produced IL-4 ( Fig. 1 , C and D) and had a significantly lower interferon-g (IFN-g)/IL-4 production ratio (Fig. 1E ) compared with those from SLE-NP patients and HCs. This was corroborated by an increased expression of T helper 2 (T H 2) transcription factor GATA-3 (GATA-binding protein 3) compared with T H 1-associated T-bet (T-box transcription factor) (Fig. 1, F and G) .
Increased iNKT cell frequency and IL-4 production in SLE-P patients compared with SLE-NP patients were associated with a switch toward CD4 positivity, a significant decrease in double-negative (CD4 Increased iNKT cell activation in SLE-P patients was corroborated in vitro by testing their proliferative capacity in response to a-GalCer (a potent iNKT cell agonist) and IL-2. SLE-P patients had increased expression of cell proliferation marker Ki-67 and increased iNKT cell frequency, similar to the HCs, showing that they had proliferated in response to a-GalCer/IL-2 ( Fig. 1 , H to J) and indicating that they had an altered functional potential compared with SLE-NP cells that did not proliferate as shown previously (9) . Furthermore, costimulatory molecule ICOS (inducible T cell costimulator), previously associated with anti-inflammatory responses, was significantly elevated in SLE-P compared with SLE-NP iNKT cells, whereas no differences were seen in the expression of CD40L after a-GalCer stimulation (Fig. 1K) . Thus, iNKT cell frequency and function were altered in SLE patients with subclinical atherosclerosis compared with SLE-NP patients.
Dyslipidemia correlated with iNKT cell phenotype in SLE-P patients We reasoned that serum factors could drive differential iNKT cell phenotype and function between SLE-P and SLE-NP patients. To test this, we cultured HC PBMCs with serum from SLE-P patients, SLE-NP patients, or heterologous HCs. Only serum from SLE-P patients induced increased iNKT cell expansion and IL-4 production similar to the ex vivo iNKT cell phenotype seen in SLE-P patients (Fig. 2, A to D) . This was prevented by the addition of blocking antiCD1d antibody (Fig. 2E) , indicating that lipid antigen presentation was required for the differential iNKT cell activation in SLE-P patients.
Because no differences in serum cytokine levels were detected between SLE-P and SLE-NP patients (fig. S3A and table S2) , we next assessed whether dyslipidemia, a risk factor for atherosclerosis, was associated with the altered iNKT cell activation in SLE-P patients. Serum lipid composition, which was analyzed using proton nuclear magnetic resonance (NMR) spectroscopy (16) , revealed elevated concentrations of very low density lipoprotein (VLDL) but not intermediate-density lipoprotein, low-density lipoprotein (LDL), or high-density lipoprotein (HDL) particles in SLE-P patients compared with SLE-NP patients ( Fig. 2F and fig. S3B ). Furthermore, significant differences were detected in the proportions of free cholesterol, cholesterol esters, phospholipids, and triglycerides carried by lipoprotein subclasses (particularly in VLDL lipoproteins) as well as other serum metabolomic components in SLE-P patients compared with SLE-NP patients (Fig.  2F, fig. S3C , and table S3). Supervised hierarchical clustering showed that differences in metabolite expression between patients with and without preclinical plaque were sufficient for the two patient groups to be segregated ( fig. S4 ). In comparison, serum lipid measures quantified in the clinical laboratory as part of routine patient management were within normal clinical ranges for our hospital. Only triglyceride levels and total cholesterol/HDL ratios were significantly elevated in SLE-P patients compared with SLE-NP patients, consistent with these being risk factors for atherosclerosis development, although no relationship with iNKT cell frequency was detected (table  S4) . iNKT cell frequency was inversely correlated with free cholesterol and phospholipid content in VLDL particles in the SLE-P patients but not in the SLE-NP patients ( Fig. 2G and table S5) , and a strong positive correlation was observed between iNKT cell IL-4 production and serum lipids-including triglycerides, cholesterol/HDL ratio, and total fatty acid ratios-in the SLE-P patients but not in the SLE-NP patients (Fig. 2, H and I, and table S5). Serum and isolated serum VLDL/LDL from SLE-NP patients increased phospholipid accumulation in HC monocytes but not in B cells compared with serum from SLE-P patients and heterogeneous HCs (Fig. 2, J and K) . Thus, serum from SLE-P patients could recapitulate the iNKT cell phenotype associated with preclinical atherosclerosis in cells from HCs, and this was associated with dyslipidemia.
Monocyte lipid antigen presentation triggers anti-inflammatory iNKT cell responses in SLE-P patients
The results suggested that changes in CD1d-mediated lipid antigen presentation by APCs could be influencing differential iNKT cell function. Therefore, we isolated cellular lipids from purified ex vivo monocytes and B cells from SLE-NP patients, SLE-P patients, and HCs (see Fig. 3A for experimental plan). Initial experiments established that iNKT cells from HCs responded more robustly to lipid fraction 5 (F5) containing phospholipids and sphingomyelin, regardless of whether lipids were isolated from monocytes or B cells (Fig. 3B) . However, only monocyte F5 lipids isolated from SLE-P patients induced a significant increase in iNKT cell expansion (Fig. 3, C and D) and a more anti-inflammatory cytokine environment, characterized by increased IL-4 and IL-13 and reduced IFN-g in tissue culture supernatants compared with SLE-NP patients or HCs (Fig. 3E) , responses that were also reversed by the addition of anti-CD1d antibody (Fig. 3, F and G) .
Thus, the results suggested that F5 lipids presented via monocyte, rather than B cell, CD1d were more effective at inducing iNKT cell and (E) ratio of iNKT cells producing IFN-g compared with IL-4. FMO, fluorescence minus one control (HC versus SLE-P, *P = 0.01; SLE-NP versus SLE-P, *P = 0.05, one-way ANOVA post t test; HC, n = 11; SLE-NP, n = 21; SLE-P, n = 21). Ex vivo iNKT cells were stained intracellularly with either T-bet or GATA-3. (F) Representative histogram and (G) cumulative data including T-bet/GATA-3 ratio. (GATA-3, *P = 0.01, one-way ANOVA post t test; HC, n = 3; SLE-P, n = 5; SLE-NP, n = 5; T-bet/GATA-3 ratio, *P = 0.05, paired t test). iNKT cell proliferation (Ki-67 expression) after 7 days of culture with a-GalCer and IL-2. (H) iNKT cell Ki-67 expression at day 0 (d0) and day 7 (d7) of culture (HC, *P = 0.01; SLE-P, *P = 0.02, paired t test; HC, n = 5; SLE-NP, n = 7; SLE-P, n = 7). (I) iNKT cell Ki-67 expression mean fluorescence intensity (MFI) at day 7 (*P = 0.01, one-way ANOVA post t test; HC, n = 6; SLE-NP, n = 8; SLE-P, n = 9). (J) Fold change in iNKT cell frequency at day 7 compared with day 0 (*P = 0.04, one-way ANOVA post t test; HC, n = 4; SLE-NP, n = 7; SLE-P, n = 8). (K) iNKT cells positive for ICOS and CD40L expression (%) at day 7 (*P = 0.01, one-way ANOVA post t test; HC, n = 3; SLE-NP, n = 5; SLE-P, n = 5). NS, not significant. Fig. 2 . Dyslipidemia was associated with altered iNKT cell activation in SLE-P patients compared with SLE-NP patients. PBMCs from four HCs were each cultured with 50% serum from five heterologous HCs, five SLE-P patients, or five SLE-NP patients + IL-2. At days 0, 4, and 7, iNKT cell frequency and intracellular IL-4 production were analyzed by flow cytometry. (A) Representative dot plots showing iNKT cell frequency at day 7 and (B) line graphs showing individual experiments (day 7, HCs 1 to 3, HC versus SLE-P, *P = 0.05, one-way ANOVA post t test; n = 5). (C) Cumulative data showing % change in iNKT cell frequency at day 7 compared with day 0 (*P = 0.01; **P = 0.001, oneway ANOVA post t test; n = 16). (D) Cumulative data showing the percentage of iNKT cells producing IL-4 at day 7 (*P = 0.05, one-way ANOVA post t test; n = 10) (E) Culture of PBMCs from an HC with serum from six different HCs, SLE-NP patients, and SLE-P patients ± blocking anti-CD1d antibody or isotype control (*P = 0.05, paired t test; n = 6). Serum from 33 SLE-P patients and 53 SLE-NP patients were analyzed by proton NMR spectroscopy for 230 serum lipid metabolites. (F) Lipoprotein size and composition between SLE-P and SLE-NP patients compared using Student's t test, converted into log −10 P value and plotted as a heat map. Higher log −10 P values (red) represent greater differences between metabolites in SLE-P patients compared with SLE-NP patients (table S2 and (G) CBA data of IL-4, IL-13, and IFN-g expression in tissue culture supernatants after 7 days of culture with SLE-P F5 monocyte lipids ± anti-CD1d or isotype control, compared with vehicle (DMSO) and a-GalCer as negative and positive controls (IL-4, **P = 0.001; IL-13, **P = 0.004, paired t test; n = 6).
activation in SLE-P patients compared with those presented by SLE-NP patients and that this triggered the production of anti-inflammatory and potentially atheroprotective cytokines (17, 18) .
iNKT cells from SLE-P patients support M2 monocyte/macrophage polarization Because monocytes are central players in the pathogenesis of atherosclerosis and express high levels of CD1d, we examined their role in iNKT cell activation in more detail. No significant differences in the expression of monocyte CD36, LDL receptor (LDLR), LOX-1 (oxidized LDL receptor-1), and LRP-1 (LDLR-related protein-1)-receptors that facilitate lipid uptake from the microenvironment or CD1d-were detected between HCs and SLE patients ( fig. S5 ). However, using a combination of monocyte gating strategies, we observed that monocytes from SLE-P patients were less inflammatory compared with those from SLE-NP patients. (19) were significantly increased in SLE-NP patients compared with HCs and SLE-P patients (Fig. 4, A and B) . Moreover, using the monocyte phenotyping strategy described by Fadini et al. (20) , the M1/M2 monocyte ratio was significantly elevated in SLE-NP patients compared with SLE-P patients and HCs, driven by increased M1-like (CD14 + CD68 + CCR2 + ) and reduced M2-like (CD14 + CD206 + CX 3 CR1 + ) monocyte frequencies in SLE-NP patients compared with HCs and SLE-P patients (Fig. 4 , C to F).
We investigated whether serum from SLE-P and SLE-NP patients and HCs could influence monocyte/macrophage polarization. Serum in the absence of T cells had no effect on in vitro polarization of M2 macrophages/monocytes detected by CD206 (mannose receptor), which is regulated by IL-4 (Fig. 4 , G and H) (21) . However, coculture of purified monocytes and T cells (containing iNKT cells) from HCs with SLE-P serum (but not SLE-NP or HC serum) preferentially induced the polarization of CD206 + M2 macrophages (see Fig. 4 , I and J, for experimental strategy). This was associated with concomitant increase in CD206 gene expression and reduced expression of M1-associated STAT-1 (signal transducer and activator of transcription-1) expression (Fig. 4K) .
To establish the role of iNKT cells in driving this process, we differentiated iNKT cells with SLE-P and SLE-NP serum and then cocultured the preconditioned iNKT cells with human THP-1 macrophages (to exclude differences between macrophages derived from HC PBMCs) (22) . Only iNKT cells exposed to monocytes and SLE-P serum induced up-regulation of CD206 and down-regulation of STAT-1 genes associated with M2 and M1 macrophage polarization, respectively, whereas no differential effect was observed with expression of other M2 (CD200R) and M1 [PPBP (proplatelet basic protein) or CD80] macrophage-associated genes [see Fig. 4 , K (for experimental strategy) and L] (23, 24). However, blocking IL-4 using anti-IL-4 blocking antibody increased STAT-1 and CD80 gene expression compared with isotype control but did not significantly influence CD206 expression, and no differential effect was observed between the patient groups (Fig. 4,  N and O) , suggesting that increased M2 monocyte/macrophage polarization was not exclusively IL-4-mediated.
SLE patients with clinical CVD lost their "anti-inflammatory" iNKT cell profile The results indicated that iNKT cells had an atheroprotective response in SLE patients with subclinical plaque. Stratification of SLE-P patients according to the number of plaque sites revealed a strong relationship between iNKT cell phenotype and plaque echolucency, a gauge of plaque stability and lipid content measured by grayscale median (GSM) [see Supplementary Materials and Methods for description of GSM assessment (25) ]. In patients with one to two plaque sites, more stable and less echolucent plaques (higher GSM score) correlated positively with iNKT cell frequency and iNKT cell IL-4 production, whereas no associations were detected in patients with more than three plaque sites or between iNKT cell phenotype and other plaque measures (fig. S6) .
To investigate this further in relation to clinical CVD, we included an additional cohort of SLE patients who had suffered a cardiovascular event (SLE-CV). Table S6 details the SLE-CV patient characteristics; no differences in serum lipid profile were detected between the SLE-P and SLE-CV groups or between SLE-P patients with one to two versus three to four plaque sites ( fig. S7, A to D) . However, SLE-CV patients had a different iNKT cell phenotype, characterized by low PB frequency, increased CD8 + phenotype, reduced CD69 expression, and low ex vivo expression of IL-4 and IFN-g compared with SLE-P and SLE-NP patients (Fig. 5, A to G) . This was associated with increased expression of proinflammatory monocytes (CD14 ++ CD16 + ) and reduced M2-like monocyte frequency (Fig. 5, H to J) . Stratification of SLE-P patients according to number of plaque sites revealed a trend toward reduced iNKT cell frequency and activation in patients with more than three plaque sites similar to patients with clinical CVD (Fig. 5 , A to J, and fig. S7D ).
Thus, SLE patients with different stages of atherosclerosis development had distinct iNKT cell phenotypes (Fig. 5K) . In particular, iNKT cells from SLE-CV patients had a "nonactivated" ex vivo phenotype and did not proliferate in response to a-GalCer stimulation ( fig. S7E ). Hence, we suggest a potential mechanism whereby in SLE-P patients, anti-inflammatory iNKT cell responses-potentially driven by dyslipidemia and altered phospholipid antigen presentation-reflect an attempt to resolve inflammatory processes during early plaque formation. In patients with clinical CVD, iNKT cells lost their antiinflammatory potential and had an "inactive" phenotype (Fig. 6 , A to C).
DISCUSSION
SLE patients have an increased risk of developing both clinically apparent CVD and subclinically atherosclerotic plaque; however, although dyslipidemia and immune dysfunction have been widely described in patients with SLE, their role in the development of atherosclerosis is not clear. Here, we identified a protective role for iNKT cells in the immune response against early atherosclerosis. Three key observations supported this conclusion. First, SLE-P patients had an iNKT cell phenotype characterized by increased activation and IL-4 production. Second, SLE-P patients had an altered serum lipid profile, in particular altered lipoprotein composition that correlated with the anti-inflammatory iNKT cell phenotype. Third, iNKT cells differentiated in the presence of SLE-P serum induced the polarization of atheroprotective M2 monocytes/macrophages.
The role of iNKT cells in human disease remains elusive; iNKT cells have a reduced PB frequency in both autoimmunity, including SLE (8, 9) , and atherosclerosis (26) , potentially due to iNKT cell migration to inflamed tissues (27) . Beyond this, little detailed information about iNKT cell phenotype in patients with atherosclerosis exists. We revealed that SLE-P patients had increased CD4 + iNKT cell number, IL-4 production, and GATA-3 expression compared with SLE-NP patients, characteristic of NKT2 cells, a functional iNKT cell subset with ) (*P = 0.008; *P = 0.015, one-way ANOVA post t test; n = 3). (K) RNA was analyzed for CD206 and STAT-1 gene expression by qPCR (CD206, *P = 0.050; STAT-1, *P = 0.049, paired t test; n = 4). (L) Experimental plan: PBMCs from two HCs were cultured with 50% serum from three different HCs, three SLE-NP patients, and three SLE-P patients for 7 days to induce iNKT cell differentiation. Isolated CD3 + T cells (including iNKT cells) were cocultured with differentiated THP-1 human macrophage cell line for 40 hours. Macrophages were analyzed for expression of M1-and M2-associated genes by qPCR. (M) Cumulative data showing M2 (CD206 and CD200R) and M1 (STAT-1, PPBP, and CD80) gene expression normalized to the level of cyclophilin (CD206, *P = 0.049; STAT-1, HC versus SLE-P, *P = 0.011; SLE-NP versus SLE-P, *P = 0.049, one-way ANOVA, post t test; n = 4) (45). HC PBMCs (n = 2) were cultured with PHS for 7 days from five HCs, five SLE-NP patients, and five SLE-P patients or IL-4 ± anti-IL-4 blocking antibody or isotype control. RNA from adherent macrophages was analyzed by qPCR. (N) Combined cumulative data for STAT-1, CD80, and CD206 expression (STAT-1, *P = 0.050; CD80, *P = 0.039, paired t test; n = 6), and (O) fold change gene expression compared with isotype (isotype = 1) for macrophages cultured in HC, SLE-NP, and SLE-P serum.
anti-inflammatory properties (28) . CD4 + iNKT cells have previously been isolated from human plaque tissue (26) and associated with T H 2 responses in HCs (29) and cancer patients (30) . However, there is no consensus on the role played by iNKT cells during preclinical atherosclerosis because they promote fatty streak formation in LDLR −/− mice (31) but have an atheroprotective role during the early stages of plaque development via increased IL-10 production (13). We found that SLE-CV patients lost the potentially protective NKT2-like phenotype and had reduced IL-4 and IFN-g production similar to iNKT cells from ApoE −/− mice with advanced plaques (11).
Our findings support marked iNKT cell phenotypic heterogeneity during human health and disease, which could be driven by factors including serum lipids or cytokines because iNKT cells can be activated by both self-antigens and foreign antigens via the iTCR and/or by iTCRindependent mechanisms via cytokine stimulation, including IL-12 and IL-18 released by APCs (32) . Standard serum lipid assessments were within normal ranges for all patients; however, the metabolomic analysis revealed a significant alteration in lipoprotein particle concentration and lipid composition between SLE-P and SLE-NP patients. We did not detect differences in the levels of IL-12 and IL-18 binding protein (essential Fig. 5 . iNKT cells from SLE patients with clinical CVD were anergic and associated with proinflammatory monocytes. Ex vivo iNKT cell frequency and phenotype in SLE-NP, SLE-P (stratified according to number of plaque sites; one to two and more than three plaque sites), and SLE-CV patients (table S5). (A) Representative dot plots and (B) cumulative data showing iNKT cell % and absolute number [**P = 0.01; *P = 0.05, one-way ANOVA post t test; SLE-NP, n = 46; SLE-P (one to two plaque sites), n = 15; SLE-P (more than three plaque sites), n = 10; SLE-CV, n = 9] and (C) frequency of iNKT cell CD8 + (*P = 0.05; **P = 0.001) and CD8 − CD4 − subsets [*P = 0.01, one-way ANOVA post t test; SLE-NP, n = 18; SLE-P (one to two plaque sites), n = 10; SLE-P (more than three plaque sites), n = 10; SLE-CV, n ) monocytes (*P = 0.05), and M1/M2 ratio [*P = 0.04; **P = 0.008, one-way ANOVA post t test; SLE-NP, n = 14; SLE-P (one to two plaque sites), n = 10; SLE-P (more than three plaque sites), n = 4; SLE-CV, n = 8]. (K) Summary of iNKT cell heterogeneity in SLE-NP, SLE-P, and SLE-CV patients relative to HCs.
for IL-18 function), which are known to promote IFN-g-mediated iNKT1 responses (33) . Nevertheless, changes in the balance between iTCR and cytokine signals could play a role in the altered iNKT cell IFN-g/IL4 ratio observed in SLE-P patients compared with SLE-NP patients, and it would be interesting to investigate further whether the trend toward reduced IL-12 levels in the SLE-P patients contributes to this process (32) .
Differences in lipoproteins are known to predict subclinical atherosclerosis in the general population (34) . However, there is little information on lipoprotein subclasses in SLE patients despite reports of defects in serum metabolite and lipid content (35) and reduced capacity of serum to sustain cholesterol efflux from THP-1 macrophages (36) . Therefore, the variations identified here in serum lipoproteins between SLE patients with and without preclinical plaque suggest that more detailed analysis of lipoprotein taxonomy could help to predict cardiovascular risk in SLE patients.
Although the exact mechanism linking serum lipids and iNKT cell activation in SLE-P patients remains to be determined, we have identified a potential role for phospholipids in driving this anti-inflammatory iNKT cell response in SLE patients. No significant differences in the expression of lipoprotein or scavenger receptors were detected on monocytes from SLE patients and HCs, potentially ruling out changes in the rate of lipid uptake. We identified differences in lipoprotein expression and lipid composition between the SLE-NP and SLE-P patient groups, and it is tempting to speculate a link between VLDL lipid content and the expansion of anti-inflammatory iNKT cells. In particular, VLDL from SLE-P serum contained increased phospholipids, which are known to activate iNKT cells (37) . However, healthy PBMC culture with VLDL purified from SLE-P patients did not influence iNKT cell phenotype; therefore, the relevance of changes in VLDL lipid composition deserves further investigation. VLDL heterogeneity is associated with early-onset atherosclerosis in autoimmunity (38) and enzymes involved in lipid processing and presentation, including lipoprotein lipase and the adipokine resistin, which have altered expression levels in SLE patients (39, 40) . Our results support previous observations that VLDL influences lipid accumulation in monocytes (41) , which could have further implications on CD1d-mediated lipid antigen presentation to iNKT cells.
Despite extensive work investigating monocyte/macrophage subsets in vitro and in animal models of atherosclerosis, evidence of their pathophysiological relevance in a clinical setting remains uncertain (21) . Previous studies on human plaques demonstrate the presence of both M1 and M2 macrophages during the development of atherosclerosis with a role for M2 macrophages during early stages (24, 42) . Using the monocyte phenotype described by Fadini et al. (20) , we show higher frequencies of M2-like monocytes in PB from SLE-P patients compared with both SLE-NP and SLE-CV patients. This was in contrast to Fadini et al. who reported increased M1-like monocytes and decreased M2-like monocytes in patients with familial and nonfamilial hypercholesterolemia with asymptomatic plaque (but no history of autoimmunity). However, the severe dyslipidemia in these patients was not seen in the SLE patients from our study, whose serum lipids were all within the standard normal range used in clinical practice.
The M1/M2-like monocyte ratio was increased in SLE-P patients compared with SLE-NP patients driven by increased M1-like and reduced M2-like monocyte frequencies in SLE-NP patients. SLE-P serum could induce M2-like macrophage polarization but only in the presence of iNKT cells. This finding corroborates previous observations in experimental autoimmune encephalomyelitis, where iNKT cell-deficient mice have fewer M2 macrophages and worse disease (43) . Similarly, in a mouse model of obesity, a-GalCer treatment significantly increased both iNKT cell numbers and M2 macrophage polarization mediated in part by IL-4 (44). We observed increased CD206 and reduced STAT-1 gene expression in adherent healthy macrophages from PBMC cultures with SLE-P serum and in THP-1 macrophages upon coculture with iNKT cells preconditioned using SLE-P serum. Although CD206 gene expression is known to be up-regulated in response to IL-4 (23, 45), blocking IL-4 increased M1 gene expression (STAT-1 and CD80) but had no effect on CD206. This suggests that iNKT cell monocyte/ macrophage cross-talk and the promotion of M2 macrophage differentiation are a more complex mechanism potentially involving other cytokines including IL-13, which was increased in response to F5 lipid stimulation (Fig. 3E) , and transactivation of other cell types (18, 44) . Conversely, during the later stages of atherosclerosis (in SLE-CV and SLE-P patients with three to four plaque sites), this protective response appeared to be reduced or overwhelmed, leading to iNKT cell exhaustion, reduced anti-inflammatory M2-like monocytes, and increased proinflammatory "intermediate" monocyte populations, in line with studies showing a predominance of M1 macrophages in more advanced ruptureprone lesions (46) (47) (48) , where the immune balance shifts from tissue repair toward chronic inflammation.
A limitation of this study is the lack of ultrasound scan data for HCs and SLE-CV patients. However, follow-up scans of SLE-NP and SLE-P patients and reassessment of their CVD history and metabolomic status will enable more detailed evaluation of how iNKT cells either protect against or promote atherosclerosis at different stages of the disease in SLE patients. Furthermore, it remains to be determined whether changes in serum lipids in SLE-P patients are potent enough to support a protective iNKT cell-mediated immune response in vivo, whether this is specific to plaque sites, or whether the protective iNKT cell phenotype is common to patients with atherosclerosis in other autoimmune diseases or atherogenesis in the absence of autoimmunity.
In summary, we show that iNKT cells could play a key role in linking the immune system, lipids, and CVD in patients with SLE. This supports the development of new diagnostic and therapeutic targets for patients at increased cardiovascular risk. Close monitoring of iNKT cell phenotype and/or serum lipid levels, because serum lipoprotein taxonomy was able to cluster patients with and without preclinical plaque, could represent a novel "bar code" to predict atherosclerosis development in SLE patients and in other at-risk patient groups.
MATERIALS AND METHODS
Study design SLE patients have an increased risk of developing clinically apparent CVD and subclinically atherosclerotic plaque, detectable by vascular ultrasound. Although dyslipidemia and immune dysfunction are widely described in SLE, their role in atherosclerosis is unclear. We propose that iNKT cells, responding to CD1d lipid antigens presented by APCs, play a key role in linking the immune system, lipids, and CVD in SLE patients. Vascular ultrasound on 100 patients with SLE but no history of CVD showed that 36% had preclinical plaque. The study had research ethics committee (06/Q0505/79) approval. Informed consent was obtained from all participants. Patient samples (SLE-P, SLE-NP, and HC) were randomly assigned to experimental groups. No statistical methods were used to predetermine sample size, which was chosen using records of variance in the past experiments.
In controlled laboratory experiments, PBMCs and serum from SLE-NP patients, SLE-P patients, and HCs were used to assess iNKT cell and CD1d + -APCs phenotype and function by flow cytometry, which was performed routinely during the 3-year study. For comparison, SLE patients who had suffered a cardiovascular event were recruited after collection of the original cohort. Serum metabolomics was performed on all scanned patients by NMR, and lipids were purified from APCs by chloroform/methanol isolation. Gene expression was analyzed using quantitative polymerase chain reaction (qPCR). In vitro cell culture experiments were performed on at least three separate occasions with different HCs and SLE patient cells and serum. Data were grouped (SLE-P, SLE-NP, and HC) for analysis. Details of exact sample numbers for each experiment are detailed in the figure legends.
Patients and controls
Carotid and femoral ultrasound scans were performed on 100 patients who met the American College of Rheumatology criteria for SLE (49) and who had no previous history of CVD. The absence of CVD (defined as coronary artery disease, stroke, or myocardial infarction with confirmatory evidence from blood tests and/or imaging) was confirmed by analysis of medical records (see Supplementary Materials and Methods for details of scanning). Eleven SLE patients who had suffered CVD events (SLE-CV) and 50 HCs were recruited but were not scanned because ethical approval was not available. Clinical, demographic, serological, therapy, and disease activity characteristics for SLE-P and SLE-NP patients, HCs (table S1), and SLE-CV patients (table S5) are shown.
Cell culture PBMCs (5 × 10 6 ) were cultured for 0 to 7 days in complete medium [RPMI 1640; 10 to 50% pooled human serum (PHS) and 1% penicillin/ streptomycin (Sigma)]. For a-GalCer-induced iNKT cell expansion, a-GalCer (100 ng/ml; Alexis Biochemicals) and IL-2 (200 IU/ml; R&D Systems) were used. In some cases, 5 × 10 6 PBMCs were cultured for 7 days in 50% serum from HCs or SLE patients ± anti-CD1d (10 mg/ml) (BD Pharmingen) or ± anti-IL-4 (InvivoGen) or appropriate isotype controls, where indicated. Alternatively, PBMCs were cultured with lipid fractions isolated from HC, SLE-NP, or SLE-P B cells or monocytes for 7 days (1:100 in complete medium, IL-2, ± anti-CD1d/isotype, as indicated). Monocyte/macrophage polarization. CD14 + monocytes were negatively isolated, CD3 + T cells (including iNKT cells) were positively isolated using magnetic beads (EasySep; Stemcell Technologies), or THP-1 cells were used as APCs. Cocultures had a 1:2 monocyte/T cell ratio, with a minimum of 5 × 10 6 cells per well. Cell culture supernatants were collected and analyzed by cytometric bead array (CBA) (BD) according to the manufacturer's instructions. THP-1 coculture. THP-1 cells (human monocytic cell line; 400,000 cells/ml in six-well plates) were cultured for 72 hours in complete medium, gentamicin (20 mg/ml), and phorbol 12-myristate 13-acetate (PMA) (5 ng/ml; Sigma); washed with phosphate-buffered saline (PBS); and rested in complete medium for 24 hours. PBMCs from HCs were incubated for 4 days with serum from heterologous HCs and SLE-NP or SLE-P patients to differentiate iNKT cells. CD3 + T cells (including iNKT cells) were positively selected using the EasySep magnetic isolation, and 1.5 × 10 6 cells were cocultured with THP-1 macrophages. After 40 hours, medium and T cells were removed, and THP-1 cells were washed once with PBS and lysed in TRIzol (Invitrogen) for RNA extraction.
Flow cytometry iNKT cell and monocyte phenotyping. PBMCs (5 × 10 6 ) were surface-stained in cold fluorescence-activated cell sorting (FACS) buffer (PBS; 1% fetal calf serum, 0.01% NaN₃, and 0.5% EDTA) using the following antibodies (from BioLegend, unless indicated): iTCR-phycoerythrin (PE) (6B11) (BD Biosciences) and CD3-APC/eFluor 780 (eBioscience) for iNKT cells [with subsets CD4-BV605, CD8-BV705, CD25-Alexa Fluor 700, CD69-BV785, PD-1-PE/Cy7, CD161-BV421, and CCR6-fluorescein isothiocyanate (FITC) (eBioscience)] and CD14-eFluor 450, CD16-APC, CD68-PE/Cy7, CX 3 CR1-FITC, CCR2-peridinin chlorophyll protein complex (PerCP)/Cy5.5, and CD206-PE for monocytes. Cells were incubated at 4°C for 20 min, washed, fixed with 2% paraformaldehyde, and resuspended in FACS buffer for analysis. iNKT cell intracellular cytokine staining. PBMCs were cultured with PMA (50 ng/ml), ionomycin (250 ng/ml), and 1:1000 GolgiPlug (BD Biosciences) for 4 hours, washed and surfacestained for iNKT cells, fixed, permeabilized (eBioscience), and stained intracellularly with IFN-g-eFluor 450 (eBioscience) and IL-4-APC. iNKT cell proliferation was assessed by intracellular staining for Ki-67-PE (BD Biosciences) or transcription factors T-bet-PerCP/Cy5.5 and GATA-3-Alexa Flour 647. Flow cytometry acquisition was analyzed using a BD LSR II flow cytometer acquiring 1 × 10 6 to 5 × 10 6 cells per sample, and data were analyzed using FlowJo version vX (Tree Star).
Phospholipid detection
Phospholipids were detected using HCS LipidTOX Phospholipidosis Detection Reagent (Invitrogen) according to the manufacturer's instructions and flow cytometry.
Lipid isolation
Cellular lipids were isolated from 1 × 10 7 FACS-sorted and PBS-washed B cells and monocytes by chloroform/methanol extraction (v/v) (50) and fractionation using aminopropyl columns (Sigma). Nitrogen-dried lipids reconstituted in 500-ml chloroform were added to columns and eluted accordingly: F1, 2 ml of diethyl ether; F2, 1.6 ml of CHCl 3 /MeOH (23:1, v/v); F3, 1.8 ml of diisopropyl ether/acetic acid (98:4, v/v); F4, 2 ml of acetone/ MeOH (9:1.2, v/v); F5, 2 ml of CHCl 3 /MeOH (2:1, v/v); F6, 2 ml of 0.2 M CH 3 COONH 4 in MeOH and 2 ml of distilled water. Fractions were dried under nitrogen, stored at −80°C, and resuspended in 50 ml of dimethyl sulfoxide (DMSO) before cell culture. Purification of serum lipoproteins with LDL/VLDL Purification Kit (Cell Biolabs) was performed according to the manufacturer's instructions followed by dialysis in PBS (Pierce) and protein quantification using bicinchoninic acid assay (Pierce).
Metabolomics
Serum metabolomic analysis was performed by Brainshake (M. Ala-Korpela, University of Eastern Finland) using a biomarker analysis platform (51) . Metabolite quantification was performed by proton NMR using two spectral windows LIPO and LMWV, giving lipoprotein subclass distribution and low-molecular weight metabolites. Models were cross-validated against NMR-independent lipoprotein and lipid data, and verified to lie within a 10% limit of the training data set.
Quantitative polymerase chain reaction RNA extraction and complementary DNA synthesis. Cells were lysed in TRIzol. RNA extraction used RNeasy Micro Kit (Qiagen) and was quantified using NanoDrop spectrophotometer. All 260:280 and 260:230 ratios were >1.9. Complementary DNA (cDNA) from 1000 ng of RNA was synthesized using AffinityScript QPCR cDNA Synthesis Kit (Agilent Technologies). qPCR was performed using Stratagene Mx3005P qPCR system and Brilliant III SYBR Green Master Mix (Agilent Technologies). Intron-spanning or intronflanking primer pairs (Sigma-Aldrich) for CD206, CD200R, STAT-1, CD80, and PPBP were designed using Primer-3, and BLAST search was performed to ensure specificity. Primers were validated and used at 100 nM.
Statistics
Values were expressed as absolute means ± SEM. Analysis was performed using GraphPad Prism (GraphPad Software) using two-tailed Student's t test, paired Student's t test, one-way analysis of variance (ANOVA), and Tukey's multiple comparison post t tests or Pearson's correlation, as specified. P values ≤0.05 were considered significant. Normal distribution was tested using Kolmogorov-Smirnov test.
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